Fischer Medical Ventures Ltd · NSE:FISCHER
Fischer Medical Ventures — Investor Presentation (September 2026)
40 slides from Fischer Medical Ventures's investor presentation, Sep 7, 2026
Slide 1: Regulation 30 intimation letter to exchanges
FISCHER MEDICAL VENTURES LIMITED Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 September 7, 2026 To To BSE Limited National
Slide 2: Investor & Strategic Partnership Presentation
INVESTOR & STRATEGIC PARTNERSHIP PRESENTATION Fischer Medical Ventures Limited Fischer Medical Ventures Limited Building the world's largest Healthcare Al Solutions Platform Al-enabled Medical Imaging I Population-scale Screening I Hospital Digitization June 2026 Confidential I Do Not Distribute
Slide 3: Legal Notice Disclaimer
BB LEGAL Notice Disclaimer Information Memorandum prepared for FMV Holdings PTE Ltd PREPARED BY FMV Holdings PTE Ltd (Fischer Medical Ventures) fo: } Purpose & Scope The information provided in this Information Memorandum is for informational purposes only and should not be considered an offer or so
Slide 4: FMV - Executive Summary
BB Executive overRvVIEW \ <a FMV - Executive Summary An integrated Al-enabled healthcare platform spanning imaging, screening, digitization and analytics 02] Medical Imaging Leadership 02 } Al Healthcare Ecosystem © Screening & Prevention Comprehensive MRI, CT, X-Ray & Mammography portfolio with pro
Slide 5: Strategic Ecosystem — FMV, Time Medical & FlynnCare
Bi croup RELATIONSHIPS Lr Strategic Ecosystem — FMV, Time Medical & FlynnCare How the three operating brands combine into one integrated healthcare innovation engine TIME MEDICAL Ws FMV ea FlynnCare fr. fiCar International Ventures Fischer Medical Ventures Health Innovations TECHNOLOGY FOUNDATION CO
Slide 6: Vision & Mission
BB STRATEGIC INTENT 4 Vision & Mission Reimagining healthcare through Al-enabled early detection and access CG Mission To make early detection and preventive healthcare To deploy Al-enabled diagnostic and screening universally accessible through intelligent, integrated platforms that digitize health
Slide 7: Our Journey So Far
Hi company JOURNEY 4 Our Journey So Far From R&D origins to a publicly-listed integrated healthcare Al platform 2008 2012 2021 2024 Foundation FDA/CE Manufacturing NSE Listing R&D in US, China, HK. IP from . R&D + manufacturing. Rights across Listed on NSE. Strong order book. Columbia & Harvard. PIG
Slide 8: Three Strategic Imaging Pillars
Hi iMaAGine PortFolio Lr Three Strategic Imaging Pillars @ TIME MEDICAL International Ventures Diagnostics, screening and interventional radiology under one platform ‘A Wholly Owned Subsidiary of A Fischer PILLAR O1 PILLAR O02 PILLAR 03 Diagnostics Screening Interventional Radiology Cd @ wri @ Vega
Slide 9: Proprietary Technology Stack
Bp Disruptive TECHNOLOGIES 4 Proprietary Technology Stack @ TIME MEDICAL International Ventures Six pillars powering best-in-class imaging performance ‘A Wholly Owned Subsidiary of A Fischer @ Magnet Technology ® RF Coil Technology @ Console Technology Permanent & LTS 0.35T/ . Multi-channel phased a
Slide 10: FMV Group Organization
■ CORPORATE STRUCTURE FMV Group Organization Integrated healthcare innovation ecosystem across diagnostics, Al, biologics and international ventures Time Medical Mr. Ravi Govindan Mercatus Capital Mr. ShankarV. Holdings Co. Ltd (Promoter) Pte Ltd (Promoter) MEDICAL TECHNOLOGY Al HEALTHCARE INTERNATI
Slide 11: FMV List of Directors
DIRECTORS FMV List of Directors Board of Directors Chairman & Managing Director Whole Time Director Independent Director Ravindran Govindan Svetlana Rao Raviwada Khairy Jamaluddin Abu Bakar • Electronics & Communications Engineer with prior • Former Chairman & President (APAC), Fisher Scientific • F
Slide 12: FMV List of Directors
DIRECTORS FMV List of Directors Board of Directors Independent Director Independent Director Independent Director Ms. Jaya Ankur Singhania Mr. Richard Chan Sing En Dr. Syed Jalaluddin • 15+ years in corporate governance and legal advisory • 30+ years in private equity and corporate finance • Disting
Slide 13: Key Managerial Personnel - FMV Group
Bp oirectors FMV KMP Key Managerial Personal- FMV Group FMV Group Chief Operating Officer Roberto M. Pagdanganan = 30+ years in investment banking, project financing, and strategic leadership = Experience across sectors including banking, telecom, tech, power etc. June 202 FMV Group Chief Financial
Slide 14: Key Managerial Personnel - FMV Group
By Directors 4 FMV KMP Key Managerial Personal- FMV Group Chief Technology Officer- Flynncare Chief Solutions Architect - Flynncare VP- Plant Operations- Time Medical (. Alagaraja Ravindra Raja Karthikeyan R Commander Yogendra Sharma = Alagaraja has more 20 years of = With over 19 years of professio
Slide 15: MRI Diagnostic Range
Bp mri portFotio MRI Diagnostic Range Six platform families covering open, closed-bore and ultra-high field segments PICA /PANION/ — AURA —- ae Ss : SS “Sh Open architecture, pediatric, weight-bearing MICA / MICA Smart “i xe General-purpose, high performance Approvals: FDA / CE /CDSCO Approvals: CDS
Slide 16: Open Architecture MRI Solutions
BB OPEN ARCHITECTURE 4 La Open Architecture MRI Solutions @ TIME MEDICAL International Ventures PICA 0.35T and AURA 0.7T — comfort, accessibility and cost-effectiveness Wholly Owned Subsidiary of AY Fischer PICA 0.35T AURA 0.7T =" Open architecture design sey __ = Best-in-class patient —_— = Higher
Slide 17: Closed Bore MRI Excellence
Bi ctosep BORE EXCELLENCE Lr Closed Bore MRI Excellence @ TIME MEDICAL International Ventures ‘AWholly Owned Subsidiary of Hs Fischer MICA, QUIN, NEONA, NEXA and Nova 7T — premium and ultra-high field imaging MICA QUIN NEONA NEXA Nova 7T Energy efficient Helium -free High- Neonatal MRI Premium clini
Slide 18: MRI Screening Portfolio
BB ScREENING SOLUTIONS SS <a MRI Screening Portfolio @ TIME MEDICAL International Ventures VEGA, VEGA+ and MMIS — purpose-built for stroke, vascular and population screening AWholly Owned Subsidiary of A Fischer = => VEGA VEGA+ A= MMIS C © Stroke Screening — Vascular & Neuro we : Mobile MRI =— es SS
Slide 19: Medharanya Suite & Intraoperative MRI
BB surcicar INNOVATION SS <a Medharanya Suite & Intraoperative MRI @ TIME MEDICAL International Ventures DRIS, DRIS+ and the integrated neuro-surgical ecosystem ‘AWholly Owned Subsidiary of Zs Fischer DRIS J Operating Room Workflow Intraoperative MRI for real-time surgical * guidance — @ Pre-surgica
Slide 20: CT Imaging Portfolio
Hct imacine CT Imaging Portfolio Clarion CT family — from 32-slice to wide-bore configurations Clarion CT 32 aa Entry diagnostic Cost-effective, high throughput IN PROGRESS Advanced Technology Enhanced Efficiency High Patient Throughput Long Tube Lifespan Clarion CT 64 Cardiac & oncology imaging IN
Slide 21: Portable X-Ray
x-ray PORTFOLIO Portable X-Ray Empowering Diagnostics Anytime, Anywhere <——_S Battery-Powered and Portable a ae ; Lightweight design with more than 150 images per a a F ~ charge using a Lithium-lon Polymer Battery. Compact size: W-228mm x D-137mm x H-188mm. Advanced Imaging Technology Versatile Clin
Slide 22: X-Ray Solutions
x-ray PORTFOLIO 4 X-Ray Solutions @ TIME MEDICAL International Ventures RX series and C-ARM — Al-enabled imaging across emergency, ward and field deployment AWholly Owned Subsidiary of “* Fischer Dn eee RX90 RX706 RX590 RX910 C-ARM Approved: CDSCO, BIS AERB; Approved: CDSCO, BIS AERB; Approved: CDSC
Slide 23: Mammography Solutions
Hy MAmm™ocrapuy 4 La Mammography Solutions @ TIME MEDICAL International Ventures Navigator series — Al-assisted breast cancer screening and tomosynthesis ‘AWholly Owned Subsidiary of AX Fischer Navigator DR CARE Navigator 3000A Al-assisted screening mammography for primary care and Advanced tomosynt
Slide 24: Integrated Healthcare Ecosystem
BE TECHNOLOGY PLATFORM Lr Integrated Healthcare Ecosystem One patient, one document — 360° patient journey on a hybrid cloud architecture > Flynn Care Health Lounge ATLAS Digital Community Care MIDAS Al Powered Analytics Integrated Diagnostic Al aw eS Al + Cloud + Data LIVE Dx Clinics 2.0 Population
Slide 25: MIDAS — Unified AI Healthcare Screening Ecosystem
| HEALTHCARE PLATFORM Lr MIDAS — Unified Al Healthcare Screening Ecosystem An integrated Al-powered platform enabling multi-disciplinary early disease detection through a single screening i} workflow (Ommm | CLINICAL WORKFLOW Oral Health Ad MIDAS Al Screening Platform Multi-Specialty Diagnostics Men
Slide 26: MIDAS — Integrated AI Screening Platform
BB Al screenine MIDAS — Integrated Al Screening Platform Multi-spectral diagnostic Al Products across eye, oral, mental, cardio-pulmonary, women's health, audiology, diabetes and cancer Cardiovascular Eye Health & Lung Health MIDAS Al Platform Preventive Treatment Molecular Nutraceutical, Wound Heal
Slide 27: Advanced AI-enabled Screening
| SCREENING DEPTH Lr Our Product Facility & Advanced Al-enabled Screening Six condition-specific Al pathways embedded into the clinical workflow Oral Cancer Breast Cancer | Cervical Screening + . = » Me Smartphone imaging Al density + lesion Colposcopy Al + HPV + Al lesion analysis on =e risk integr
Slide 28: LIVE Dx — Population Screening Platform
Bp Poputation PLATFORM 4 LIVE Dx — Population Screening Platform Population-scale screening with tele-health, remote monitoring and predictive analytics 2 3 4, 5 Screen Risk Stratify Triage Treat & Monitor VY ; Citizen identity & consent Multi-modal Al screening. Predictive risk scoring Al-driven ro
Slide 29: Clinics 2.0 Platform
BB Hospital DIGITIZATION Clinics 2.0 Platform Specialty EHR, HIS, practice management, telemedicine, Al insights and device interoperability Specialty EHR Specialty-specific clinical templates Telemedicine ec Integrated video CI os consults & e- = WN prescriptions Registration Consult June 2026 HIS
Slide 30: ATLAS — AI Healthcare Analytics Platform
Bp Anatytics ATLAS — Al Healthcare Analytics Platform From descriptive to prescriptive — a four-stage analytics maturity engine @ Digital Twin Framework ® Real-World Data Analytics © Al/ML Healthcare Intelligence ai en aS fa a a Descriptive Diagnostic Predictive Prescriptive What happened? Why did i
Slide 31: FlynnCare Healthcare Deployment Model
Bp ivetemenraTioNn MODELS FlynnCare Healthcare Deployment Model Layered care architecture from primary screening to tertiary intervention Centre of Excellence - Advanced analytics - MIS reports FINN. CARE:PLATFORM - Real World Data for Clinical Research - Big data analytics platform - Encompasses al
Slide 32: NanoMedic — SpinCare Regenerative Skin Technology
Bi Portrotio COMPANY IN NanoMedic — SpinCare Regenerative Skin Technology World's first portable electrospinning system for direct-to-patient regenerative skin substitute application NanoMedic First-in-class - Wound Care = ° i {AAS » Worla's only portable electrospinning sy: Direct-on-patient Single
Slide 33: Obelab — Portable Brain Imaging Platform
BB PorTFOLIO COMPANY Lr Obelab — Portable Brain Imaging Platform Functional! near-infrared (fNIRS) and cerebral oximetry devices for research and clinical mental-health care Portfolio Focus O be la b A multi-device platform covering high-resolution fNIRS research systems and clinical cerebral oximet
Slide 34: Nervotec — Contactless Vital Signs Measurement
Bp PortFOLIO COMPANY \ <a Nervotec — Contactless Vital Signs Measurement Predictive healthcare via a 60-second facial scan — no wearables, no contact, no hardware Nervotec Singapore-headquartered - Al-driven Empowers predictive healthcare — contactless, remote, smartphone-only — capturing vitals and
Slide 35: Nanyang Biologics — AI Drug Discovery Platform
Hp Portrotio COMPANY SS <a Nanyang Biologics — Al Drug Discovery Platform Next-generation natural-compound drug discovery built on NVIDIA + HPE infrastructure with NTU joint research . . PROPRIETARY LIBRARY OF MILLIONS OF NATURAL DRUG COMPOUNDS Nanyang Biologics Bundled Al software + hardware soluti
Slide 36: Nanyang Biologics — CareViva Nutraceutical Portfolio
Hp Portrotio COMPANY rN Nanyang Biologics — CareViva Nutraceutical Portfolio Evidence-based, scientifically backed nutraceutical products across oncology, metabolic, liver and cardiovascular health 8 Natural CAneviVA, ‘== Support ecer Tumour protection PROVEN EFFICACY Inhibits tumour growth without
Slide 37: 4T4TB — TB Screening Framework
Mrs FRAMEWORK Lr» 4T4TB — TB Screening Framework Trace, Test, Treat, Track — an Al-enabled portable X-ray driven workflow Trace Test Treat Track Community case finding + Al Portable X-Ray + Al pre-read + DOTS initiation + adherence Outcome tracking + contact cough analysis sputum testing monitoring
Slide 38: SHIELD — Cancer Screening Framework
BB cancer FRAMEWORK Lr SHIELD — Cancer Screening Framework Screen, Highlight, Investigate, Empower, Long-term monitoring, Develop Screen Highlight Investigate Empower Long-term Develop @ ee eco BIS = =} A W Population-wide Al Risk-stratify and flag Confirmatory imaging & Patient education & Surveill
Slide 39: Corporate Health Screening
BB CORPORATE HEALTH Lr Corporate Health Screening Workforce wellness, women's health, mental wellness and ESG-linked healthcare Workforce Wellness Preventive Care Women's Health Mental Wellness ESG-linked Health v 2, 4 6 NY Annual health checks + risk Pathways for hypertension, Breast, cervical, fer
Slide 40: Thank You
Thank You FMV: Building the world's largest Healthcare Al Solutions Platform. Investor & Strategic Partnership Engagements Disclaimer: Certain statements in this document maybe forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government
Fischer Medical Ventures — Investor Presentation (September 2026) on 6ix